"Unmet Needs in the Treatment of Rheumatoid Arthritis"
written by Janet Pope, Bernard Combe,
published by Open Journal of Rheumatology and Autoimmune Diseases, Vol.3 No.2, 2013
has been cited by the following article(s):
  • Google Scholar
  • CrossRef
[1] Tofacitinib in the treatment of moderate-to-severe rheumatoid arthritis: a cost-effectiveness analysis compared with adalimumab in Taiwan
2019
[2] Rheumatoid Arthritis Treatment. A Back to the Drawing Board Project or High Expectations for Low Unmet Needs?
2019
[3] The anti‐CD6 antibody itolizumab provides clinical benefit without lymphopenia in rheumatoid arthritis patients: results from a 6‐month, open‐label Phase I clinical …
Clinical & Experimental Immunology, 2018
[4] Unmet needs in the treatment of Rheumatoid Arthritis. An observational study and a real-life experience from a single university center.
Seminars in Arthritis and Rheumatism, 2018
[5] Tofacitinib, an oral Janus kinase inhibitor, in patients from Brazil with rheumatoid arthritis: Pooled efficacy and safety analyses
Medicine, 2018
[6] Activity Engagement of Young Adults with Autoimmune Arthritis: A Multi-Method Approach
2018
[7] Thank you to our reviewers
2016
[8] Therapeutic Targeting of CD6 in Autoimmune Diseases: A Review of Cuban Clinical Studies with the Antibodies IOR-T1 and Itolizumab
Current Drug Targets, 2016
[9] Comparative assessment of clinical response in patients with rheumatoid arthritis between PF‐05280586, a proposed rituximab biosimilar, and rituximab
British Journal of Clinical Pharmacology, 2016
[10] Sonodelivery Facilitates Sustained Luciferase Expression from an Episomal Vector in Skeletal Muscle
Materials, 2015
[11] Current Understanding of the Pathogenesis of Rheumatoid Arthritis, Unmet Needs in Treatment, Ongoing Research and the Future
2015
[12] СОВPEМЕННАЯ
2013
[13] Новые направления фармакотерапии ревматических заболеваний—ингибиция интерлейкина 6 и интерлейкина 17
2013
[14] INTERLEUKIN-17 IS A NEW TARGET FOR ANTI-CYTOKINE THERAPY OF IMMUNE INFLAMMATORY RHEUMATIC DISEASES
Rheumatology Science and Practice, 2013
[15] ИНТЕРЛЕЙКИН 17—НОВАЯ МИШЕНЬ ДЛЯ АНТИЦИТОКИНОВОЙ ТЕРАПИИ ИММУНОВОСПАЛ
Научно-практическая ревматология, 2013
[16] New areas of the pharmacotherapy of rheumatic diseases are inhibition of interleukin-6 and interleukin-17
Modern Rheumatology Journal, 2013
[17] ИНТЕРЛЕЙКИН 17—НОВАЯ МИШЕНЬ ДЛЯ АНТИЦИТОКИНОВОЙ ТЕРАПИИ ИММУНОВОСПАЛИТЕЛЬНЫХ РЕВМАТИЧЕСКИХ ЗАБОЛЕВАНИЙ
Научно-практическая ревматология, 2013